Please login to the form below

Not currently logged in
Email:
Password:

Evotec invests €15m in AI firm Exscientia

Funds will help the Scottish group accelerate growth

EvotecDrug discovery platform group Evotec has invested €15m in artificial intelligence firm Exscientia, and becomes the first strategic shareholder of the Scottish group.

Building on a partnership that begun in 2016 to discover novel immuno-oncology therapeutics, the new funds will see Exscientia expand its automated design platform and drive higher value partner programmes.

Dr Werner Lanthaler, chief executive officer, Evotec, said: “Our investment in Exscientia represents Evotec’s single biggest equity placement to date and in, what we feel is, the world leading AI technology company.”

The University of Dundee spin-out was the first company to automate drug design “surpassing conventional approaches” and “improving drug efficacy”.

Lanthaler continued: “Working with Exscientia on a joint immuno-oncology project over the past year, we have experienced first-hand how its AI approaches, along with our medicinal chemistry platform, can positively and radically impact drug discovery.”

Evotec is not the only pharmaceutical-based company who has partnered up with the AI firm however, as Sanofi signed a deal earlier this year to develop bispecfic small-molecule drugs to treat metabolic diseases.

GlaxoSmithKline also hopped on the AI bandwagon, collaborating with Exscientia back in July focusing on ten targets across multiple therapeutic areas.

Prof. Andrew Hopkins, chief executive officer, Exscientia, said: “Exscientia and Evotec have built a close relationship over the past year sharing mutual interest in agile innovation.

“We are delighted that Evotec has made this investment for a minority equity stake, allowing Exscientia to deliver more drug discovery projects in a rapid and capital efficient manner.”

As per the investment, Evotec’s chief operating officer, Dr Mario Polywka, will join Exscientia’s board of directors.

Article by
Gemma Jones

31st October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....